Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126796182 | 12679618 | 2 | F | 201608 | 20160907 | 20160824 | 20160909 | PER | US-PFIZER INC-2016394544 | PFIZER | 60.00 | YR | M | Y | 0.00000 | 20160909 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126796182 | 12679618 | 1 | PS | VIAGRA | SILDENAFIL CITRATE | 1 | Oral | 100 MG, UNK (100MG TABLET BY MOUTH ABOUT AN HOUR BEFORE FOREPLAY) | A599101S | 20895 | 100 | MG | FILM-COATED TABLET | ||||||
| 126796182 | 12679618 | 2 | SS | VIAGRA | SILDENAFIL CITRATE | 1 | Oral | 50 MG, UNK (ONCE OR TWICE A DAY) | 20895 | 50 | MG | FILM-COATED TABLET | |||||||
| 126796182 | 12679618 | 3 | C | POTASSIUM | POTASSIUM | 1 | Oral | 20 MEQ, 1X/DAY | 0 | 20 | MEQ | TABLET | QD | ||||||
| 126796182 | 12679618 | 4 | C | ANDROGEL | TESTOSTERONE | 1 | 1 PUMP AND A HALF ON EACH SIDE EVERY DAY IN THE MORNING | 0 | |||||||||||
| 126796182 | 12679618 | 5 | C | NAPROXEN. | NAPROXEN | 1 | 500 MG (ONE IN THE MORNING AND ONE AT NIGHT) | 0 | 500 | MG | |||||||||
| 126796182 | 12679618 | 6 | C | DEPAKOTE | DIVALPROEX SODIUM | 1 | Oral | 250 MG (1 ON THE MORNING AND 2 AT NIGHT) | 0 | 250 | MG | TABLET | |||||||
| 126796182 | 12679618 | 7 | C | LORAZEPAM. | LORAZEPAM | 1 | Oral | 1 MG (ONE IN THE MORNING AND 2 IN THE EVENING) | 0 | 1 | MG | TABLET | |||||||
| 126796182 | 12679618 | 8 | C | ULORIC | FEBUXOSTAT | 1 | 40 MG, 1X/DAY | 0 | 40 | MG | TABLET | QD | |||||||
| 126796182 | 12679618 | 9 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | 10 MG, 1X/DAY | 0 | 10 | MG | TABLET | QD | ||||||
| 126796182 | 12679618 | 10 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 500 MG, 1X/DAY | 0 | 500 | MG | TABLET | QD | ||||||
| 126796182 | 12679618 | 11 | C | DOXAZOSIN | DOXAZOSINDOXAZOSIN MESYLATE | 1 | Oral | 4 MG, DAILY (ONCE AT NIGHT) | 0 | 4 | MG | TABLET | |||||||
| 126796182 | 12679618 | 12 | C | CINNAMON PILL | 2 | 1000 MG, DAILY (500MG TWO PILLS PER DAY) | 0 | 1000 | MG | ||||||||||
| 126796182 | 12679618 | 13 | C | FISH OIL | FISH OIL | 1 | 1000 MG, DAILY | 0 | 1000 | MG | GEL | ||||||||
| 126796182 | 12679618 | 14 | C | MAGNESIUM | MAGNESIUM | 1 | Oral | 250 MG, 2X/DAY | 0 | 250 | MG | TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126796182 | 12679618 | 1 | Erectile dysfunction |
| 126796182 | 12679618 | 3 | Blood potassium decreased |
| 126796182 | 12679618 | 4 | Blood testosterone decreased |
| 126796182 | 12679618 | 5 | Arthritis |
| 126796182 | 12679618 | 8 | Gout |
| 126796182 | 12679618 | 9 | Blood cholesterol increased |
| 126796182 | 12679618 | 10 | Diabetes mellitus |
| 126796182 | 12679618 | 11 | Prostatic disorder |
| 126796182 | 12679618 | 12 | Blood glucose abnormal |
| 126796182 | 12679618 | 13 | Cardiac disorder |
| 126796182 | 12679618 | 14 | Nutritional supplementation |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126796182 | 12679618 | Drug ineffective | |
| 126796182 | 12679618 | Intentional product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126796182 | 12679618 | 1 | 201608 | 0 | ||
| 126796182 | 12679618 | 2 | 20160802 | 20160829 | 0 |